Organization Profile

You just read:

Phase 1 Study of OGX-427 Presented at the ASCO 2012 Genitourinary Cancers Symposium Shows Early Evidence of Activity in Bladder Cancer

News provided by

OncoGenex Pharmaceuticals, Inc.

Feb 02, 2012, 08:01 ET